The purpose of this research was to see if switching from insulin glargine to insulin detemir would help better the financial costs for treatments or improve the effects of the treatments for type 2 diabetes patients. Type 2 diabetes patients went through a trial in which patients were given one insulin for treatment then switched later on. The patients first started with a daily prescription of insulin glargine for at least 6 months. Then, after at least 6 months, the patients' prescription would change into insulin detemir for the following 6 months. The results proved insulin detemir increased the average A1c levels. Also, the patients did lose weight, but not a significant amount. However, patients need more of insulin detemir daily than insulin glargine. In conclusion, the insulin detemir was cheaper than insulin glargine and proved to help decrease the type 2 diabetes patients' weight by a little amount. Bernadette D. Asias, Eileen M. Stock, Nancy L. Small, Katerine E. Getchell, Jagruti R. Patel, Jennifer D. Krause, Staci Cavness,Cassidy L. Dzenowski and Mia Ta. "Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes" Journal of Diabetes & Metabolic Disorders.(2015).Web. |
Assignments > How to Read a Journal Article >